STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

SLU-PP-332

Also known as

SLU PP 332 · SLUPP332 · SLU-PP332 · SLU-PP 332 · ERR pan-agonist (SLU-PP-332) · ERR agonist exercise-mimetic discussion compound · Saint Louis University PP-332 · CAS 303760-60-3

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Lots of talk Systemic Oral / SubQ Metabolic research compounds

Systemic pan-ERR research aimed at fuel use and muscle oxidative programs; published efficacy is in mice, not local injection-site repair.

What people say SLU-PP-332 is a synthetic small-molecule pan-ERR agonist studied as an exercise-mimetic research tool in mice; it is not a peptide or an approved human drug. Doses people talk about
Progressive oral account2 mg/day; 6 mg/day split; later 10 mg

2 mg oral daily for 2 weeks; 6 mg/day in 3 doses for 2 weeks; week 5: 10 mg at once, stopped after 3 days; later 10 mg on alternate days. One author reported uncertain energy, then exhaustion, evening crash and sleep disruption, followed by the rest of that week off. Calorie deficit and activity confound this changing-dose account; it is not an escalation recommendation.

Null oral account200 mcg each morning for 21 days; then 300 mcg before stopping

A separate author reported no benefit and discarded the remainder; the labeled material and exposure were not verified.

Mouse efficacy studies25–50 mg/kg intraperitoneal, often twice daily for about 12–28 days

Protocol-specific animal research across endurance and metabolic models, not a human-equivalent regimen.

Both human oral and SubQ discussion concern unverified products; the selected firsthand courses are oral. Mouse mg/kg is not a human recommendation, and human identity, exposure, safety and efficacy remain unverified.

Half-life & effect duration

Half-life in the body
  • Community / secondary estimateAbout 1.5 hours
Felt duration people report
  • Injected-use community reportsWarmth, flushing or a cardio-ready feeling within about 20–60 minutes
  • Other accountsNo benefit, uncertain energy or endurance changes
  • Other experiencesEvening fatigue, crashes or difficult sleep during repeated use
Timing context & sources
How it may feel Inspected oral reports conflict, ranging from no benefit at labeled microgram amounts to mixed energy, crash and sleep observations during a progressive milligram course.
Cycles people discuss Community notes describe short trial blocks, while mouse studies use protocol-specific repeated dosing; there is no pharmacology-backed human washout or cycle standard. Timing Legacy notes favor morning or pre-activity timing; one oral author reported morning use while fasting until lunch and avoiding bedtime after sleep disruption. Meal effects on exposure remain unmeasured. Stacks The preserved notes most often name 5-Amino-1MQ, but no controlled human combination data establish benefit or safety and multi-agent use obscures attribution. Watch for Unknown human safety: No large human safety database; long-term cardiac, hepatic, endocrine, and oncologic risk of chronic pan-ERR agonism is open.
Related
CardarineSLU-PP-915GW0742BAM15MOTS-c

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

No dependable human half-life, oral bioavailability or systemic exposure profile was established for SLU-PP-332.

The formal literature uses mouse intraperitoneal dosing and reports parent SLU-PP-332 lacks oral bioavailability in the comparison that produced orally active SLU-PP-915. Neither result supplies human PK.

Mouse tissue exposure, repeated IP dosing and a mouse oral-activity comparison cannot establish human half-life, Cmax, AUC or retail oral exposure.

Felt duration people report

Unverified self-reports range from no benefit to mixed energy, crash, fatigue and sleep observations, without a reproducible onset or duration.

exbrowser422 described no clear effect at oral 2 mg/day for two weeks, uncertain energy at 6 mg/day in three doses for two weeks, then exhaustion and difficult sleep after three days of 10 mg at once, the rest of that week off and later alternate-day 10 mg; a 200–500 kcal deficit, steps and activity complicate attribution. Human-Lemon7620 separately reported no benefit at oral 200 mcg each morning for 21 days, then attempted 300 mcg and discarded 15 tablets. A third author, Character_Medium_484, described four days at claimed 400 mg/day split between morning and noon, evening fatigue and sleep increasing from 5–6 to 8 hours, with NAD+ 100 mg SubQ, coffee/creatine, fasted cardio, resistance training and changing food intake. The same author later reported improved fatigue after that morning’s 200 mg; earlier month-long 250 mcg and then 100 mg attempts were described as unhelpful. The SubQ route in this third account belongs to NAD+, not an explicitly identified SLU route.

Distinct uncontrolled authors, extreme amount differences, unverified labels/identity, changing courses, co-exposures, food/activity changes and no measured exposure; no prevalence or causal dose-response can be inferred.

  • SLU-PP-332 experience dosage test (opens in a new tab)exbrowser422 opening chronology: oral 2 mg/day weeks 1–2; 2 mg three times/day (6 mg/day) weeks 3–4 with uncertain attribution; week 5 five 2 mg tablets at once (10 mg), exhaustion after three days, difficult sleep and remainder of week off; week 6 onward 10 mg on alternate days. Opening diet/steps context and same-author morning/fasted-until-lunch/avoid-bedtime follow-up were reviewed.One uncontrolled changing-course account with a reported 200–500 kcal deficit and activity/steps, unverified product/exposure and expectancy confounding; not a dose-response or escalation protocol.
  • SLU-PP-332: my experience (opens in a new tab)Human-Lemon7620 opening: 200 mcg oral each morning, fasted, for 21 days without perceived benefit; attempted 300 mcg. Update 29/05/2024: remaining 15 tablets discarded. This is a 2024 microgram account, not proof of a unit error in a different inherited 2026 high-mg report.Single unblinded report, unverified product and labeled amount, no exposure measurement, narrow outcome description and no control.
  • Any experience with high-dose SLU-PP-332? (opens in a new tab)Character_Medium_484 opening and same-author replies, including comment branch nlzs3ft: four days at claimed 400 mg/day split 200 mg on waking and 200 mg at noon; evening fatigue and sleep 5–6 to 8 hours, with NAD+ 100 mg SubQ, coffee/creatine, fasted cardio, resistance exercise and later increased food intake. Same-author follow-up describes improved fatigue after morning 200 mg and earlier month-long 250 mcg then 100 mg attempts without attributable benefit. SubQ explicitly describes NAD+; the inspected text does not explicitly establish SLU route.Extreme unverified SLU amount, identity, formulation and route; substantial co-exposures, exercise/food changes and changing observations across replies. Other authors are separate, and no measured exposure or causal response is established.

What people say 11

  • Lean-mass talk: Preclinical summaries emphasize fat down with lean largely spared — animal-only; human recomp claims are confounded. animalforum
  • Community inject logs: Warmer feel, easier cardio, sweats, gradual fat-loss assist under deficit — highly confounded by diet/training/stack; attribution unreliable. forumanecdote
  • Community oral logs: Split hard — null reports at 250–500 mcg capsules vs “felt energy / peeled fat” at multi-mg to tens-of-mg oral bulk talk; oral F is the main dispute. forum
  • Evidence honesty: Mouse metabolic/endurance package is real and citable; human efficacy at retail capsule doses is unproven; allometric mouse→human dose math is not clinical dosing. trialforum
  • 2026 915-switch logs: People who felt nothing on oral 332 (including high-mg and sublingual tries) often reframe the next experiment as oral 915 rather than “ERR does nothing.” Purity and dose still confound attribution. forumanecdote
  • Endurance (mice): ACS Chem Biol 2023 — treated mice ran ~70% longer and ~45% further; shift toward type IIa oxidative fibers vs vehicle. animal
  • Fat mass / weight (obese mice): Multi-week IP dosing limited fat gain vs vehicle; UF/media summaries of DIO work cite ~10× less fat gain and ~12% body-weight reduction over ~1 month without reduced food intake. animal
  • Fuel shift: Acute RER drop (more fat oxidation) within hours of dose in mice; chronic work reports substantially higher fatty-acid oxidation (community/vendor summaries often cite ~25% — check primary paper for exact figure). animal
  • Energy expenditure: Higher whole-body energy burn in metabolic cages without more spontaneous movement or less chow in published models. animal
  • Metabolic markers (mice): Better glucose tolerance, lower insulin/glucose signals, improved triglycerides / less hepatic fat signals in DIO and ob/ob models (Billon metabolic-syndrome papers; ~12–28 day regimens). animal
  • Cardiac (mice, disease model): Xu et al. Circulation 2023 — pan-ERR agonism (SLU-PP-332 / related) improved ejection fraction, reduced fibrosis in pressure-overload HF model without pathological hypertrophy (preclinical, not human clearance). animal

Doses people talk about 16

  • Allometric caution: Naive BSA scaling of 25 mg/kg mouse can imply ~100+ mg/day human-equivalent order of magnitude; community injectable protocols sit far below that for cost and caution — efficacy at those fractions is unproven. forumtrial
  • Oral retail micro-capsules: Very common SKU is ~250 mcg (0.25 mg) per cap; community starts often 250–500 mcg/day oral, sometimes BID. Widely attacked as “placebo tier” given oral-F literature. forum
  • Oral mid / bulk-powder culture: Multi-mg daily (e.g. ~1–10+ mg) and higher “tens of mg” oral talk; Instagram/forums also discuss ~20–100 mg oral sweet-spot lore and even higher experimental runs — none are validated human PK doses. forumanecdote
  • High oral mg lore vs potency argument: Some influencers push 50–400 mg oral runs; counter-threads argue nanomolar ERR potency means systemic 0.2–1 mg may already saturate if exposure is real — both camps lack human PK. forum
  • Community injectable (SubQ research material): Commonly discussed ~250–500 mcg/day start; typical cluster ~500 mcg–1.5 mg/day; some protocols 1.25–2.5 mg/day BID-split; titration stories 0.25 → 0.5 → 0.75 mg over weeks. forum
  • Split dosing: BID (and sometimes TID) mirrors short mouse coverage and short circulating half-life talk; morning + pre-cardio or morning + afternoon appears often. animalforum
  • Route hierarchy in serious threads: Published IP (mice) → experimental SubQ (community) → oral capsules (debated / often dismissed) → sublingual liquids (marketed to bypass gut; no published F). trialforum
  • vs SLU-PP-915: 915 was engineered for oral activity; 332 is the classic IP tool. Brows looking for “oral ERR pill” increasingly search 915 instead. trialforum
  • Enteric-coat workaround camp: 2026 r/SLUPP332-style replies say 332 “is not orally bioavailable at all” unless capsules are acid-resistant/enteric — most bottles are not. Unproven as a fix. forum
  • The ~45% oral-BA number: Forum archaeology treats a circulating ~45% rodent oral-F figure as Wikipedia/social fabrication, not a primary PK table. forum
  • High-oral debate / separate inspected courses: Inherited 2026 Jay-style influencer notes argue that high-mg oral 332 can show n=1 activity without a fatty meal, against the “oral 332 is dead” camp; that specific legacy claim remains unlocated and does not establish human PK. Separately, exbrowser422 described 2 mg oral daily for two weeks, 6 mg/day in three doses for two weeks, then 10 mg at once in week 5, stopping after three days of exhaustion and difficult sleep, resting the rest of that week and later using 10 mg on alternate days. Human-Lemon7620’s distinct null course was 200 mcg daily for 21 days, then an attempted 300 mcg. Identity, exposure and attribution remain unverified. forum
  • DMSO inject hassle: SubQ/research-chem 332 often needs a small-molecule solvent story (DMSO talk) unlike a peptide BAC-water vial — a reason people jump to oral 915. forum
  • Identity / assay risk: Labeled mcg vs mg SKUs, underfilled caps, and wrong molecule risk make “I took X and felt nothing” hard to interpret without independent testing. forum
  • Framing: Every human figure below is community / research-chem discussion or allometric guesswork — not clinical dosing, not medical advice, not consumption guidance. forum
  • Mouse efficacy (primary literature): Roughly 25–50 mg/kg intraperitoneal, often twice daily (BID), for ~12–28 days depending on model (endurance, DIO, ob/ob). Billon ACS Chem Biol / J Biol Chem line; MedChemExpress and related datasheets echo 50 mg/kg IP BID for metabolic endpoints. animaltrial
  • Mouse acute / PK sampling: Exposure work often cites ~30 mg/kg IP single dose with plasma and muscle still measurable at 2–6 hours (muscle > plasma in some summaries). animal

How it may feel 10

  • Minutes–hours injection lore / distinct oral course: Inherited SubQ/experimental-injection reports describe warmth, mild flush, feeling “primed for cardio” or elevated perceived HR within ~20–60 minutes; others report nothing the same day. These are unverified route-specific legacy reports, not a typical onset. Separately, exbrowser422 reported oral 2 mg daily for weeks 1–2 with no clear effect, 2 mg three times daily (6 mg/day) for weeks 3–4 with uncertain energy changes, then 10 mg at once in week 5. After three days they described exhaustion and difficult sleep, skipped the rest of that week, then used 10 mg on alternate days from week 6. Calorie deficit, steps and activity confound attribution. forumanecdote
  • Hours 1–6: Mouse RER / acute transcriptional program shifts fast after IP; human “same-day feel” is not the same as multi-week body-comp change. animalforum
  • Days 1–7: Commonly null or subtle unless stacked or dosed higher; oral micro-capsules especially often “nothing.” forum
  • Weeks 1–2: Community endurance / sweat / energy checkpoints; mouse fat-mass curves also start moving in first 1–2 weeks of high IP BID regimens. animalforum
  • Weeks 2–4: Most common human-log window for “cardio easier” or scale claims; non-responders usually reassess route (oral vs inject), dose, purity, and deficit. forum
  • Weeks 4–8: Body-comp anecdotes cluster here when a calorie deficit is present; continuous human safety still unestablished. anecdoteforum
  • No change by ~3–4 weeks: Forums first blame oral absorption / underdosing / fake powder / under-filled caps before mechanism. forum
  • Long use: Sparse clean multi-month solo logs; most blocks are short research-chem runs. forum
  • Oral null reports, distinct amounts and years: Inherited 2026 notes include an unlocated n=1 “200 mg oral and I never felt anything” report alongside the high-mg activity debate. A separate inspected 2024 author, Human-Lemon7620, reported no benefit after 200 mcg each morning for 21 days, then attempted 300 mcg before discarding the remaining 15 tablets. This source does not establish that the older 200 mg claim was a unit error. A different 2026 progressive 2-to-10 mg course included uncertain energy, exhaustion, a rest-of-week gap and later alternate-day use. anecdote
  • 915 versus 332 feel talk: Inherited 2026 notes contrast ~10 mg oral 915 as slower/steadier with ~500 mcg SubQ 332 as shorter/sharper. This unverified n=1 chemistry-plus-route comparison is retained as legacy discussion, not a human head-to-head result. Separately, the inspected formal program reports oral activity for the chemically distinct SLU-PP-915 and lack of parent SLU-PP-332 oral bioavailability in mice; it cannot validate that human feel comparison. anecdoteanimal

Around the dose 6

  • Clock: Inherited n=1 charts favor morning / pre-activity rather than night use; this is reported habit, not a validated dosing time. In the inspected progressive oral account, exbrowser422 described morning use while fasting until lunch and avoiding bedtime because of sleep disruption. forum
  • Training context: Legacy notes market the compound as an exercise mimetic and associate reports with cardio or lifting; the inspected oral author also described a calorie deficit and steps. These co-factors confound attribution, and no human exercise-replacement benefit is established. forum
  • Food: Oral; some run it fasted, some don’t. No locked meal ritual yet. forum
  • After: Zone-2 or steps on dose days is the habit that shows up in diaries. forum
  • Fasted vs food: Inherited 2026 high-oral discussion claims a fatty meal is unnecessary, while other legacy notes describe taking it with food for stomach comfort; neither is an established exposure result. The inspected morning-fasted oral accounts do not prove either claim, and no human oral-bioavailability study was established. forum
  • 915 fork: If the goal is a convenient oral ERR pill, 2026 threads often stop the 332 capsule experiment and look at 915 instead of stacking both. forum

Cycles people discuss 8

  • First trial length: 2–4 weeks is a common community “see if anything happens” block. forum
  • Extended body-comp blocks: 4–8 weeks on is the modal longer run discussed for fat-loss / recomp goals. forum
  • Time off: Many logs use roughly equal off (e.g. 4–8 weeks off) or informal 1–2 week breaks; no pharmacology-backed washout standard. forum
  • Continuous vs pulsed: Some daily open-ended while cutting; others pulse around prep or cardio blocks — no consensus protocol. forum
  • 5 on / 2 off: Appears in some oral-protocol blogs; not literature-derived. forum
  • Restarts: Common after off periods; restarts without standard re-titration science. forum
  • Mouse study lengths: Often ~12 days (ob/ob) to ~15–28 days continuous IP BID depending on endpoint. animal
  • Long-term human safety: Not established — continuous multi-month / multi-year use has no clinical database. trial

Timing 8

  • Secondary half-life shorthand / human PK gap: Inherited community/blog summaries cite ~1.5 hours in serum and similarly short tissue half-lives. That unverified secondary shorthand is not an established human PK value unless tied to an appropriate primary table. The inspected mouse exposure and SLU-PP-915 comparison do not establish human half-life, oral bioavailability, Cmax or AUC for SLU-PP-332. forumtrial
  • Feel vs results: Same-day heat/energy ≠ multi-week fat loss; gene programs and training/deficit dominate longer arcs. anecdoteforum
  • Mouse exposure window: After ~30 mg/kg IP, plasma and muscle still detectable at ~6 hours in Billon-line PK sampling (muscle concentrations often higher than plasma at 2 h in secondary write-ups). animal
  • Animal coverage interpretation: Multi-dose/day (BID) mouse schedules are interpreted in inherited notes as seeking sustained tissue exposure rather than a weekly depot. The schedule alone does not measure elimination or establish human coverage or redosing intervals. animal
  • Acute biology timing: Mouse RER / exercise-gene signature can shift within ~1–2 hours of first dose. animal
  • Human PK: No solid public oral F, SC bioavailability, Cmax, AUC, or steady-state numbers for research-chem material. trial
  • Downstream: Nuclear-receptor transcriptional programs can outlast peak blood levels (biology inference, not a measured human half-life of effect). trial
  • Metabolism (anti-doping): In-vitro human-liver work characterized multiple Phase-I and Phase-II metabolites of SLU-PP-332 (distinct pattern vs SLU-PP-915) — relevant to detectability, not efficacy. trial

More on what it is 8

  • Why the hype: 2023 mouse papers (Billon et al.) framed it as an “exercise mimetic”: more treadmill endurance and less fat mass without extra running or less food. Media + forum explosion followed. animalforum
  • What it is not: Not a SARM, not cardarine/PPARδ, not a GLP-1, not a training substitute, not pharmacy-compounded medicine. forum
  • Oral caveat (core bro fight): Later Burris/SLU-PP-915 work states parent SLU-PP-332 lacks oral bioavailability — mouse efficacy used intraperitoneal injection. Retail capsules/tablets sit in a “placebo vs high-mg oral lore” split. trialforum
  • Identity: Often mis-sold as a “peptide”; it is a lipophilic small molecule with different solubility rules than BPC/TB-class vials. forum
  • 2026 oral-F fight (vs 915): r/SLUPP332 and X line is “get 915 if you want a swallow.” Burris-line / JPET-class writeups (Billon et al.; community cites PMID 41421047) say parent 332 lacks oral bioavailability, which is why 915 exists. Retail 332 capsules sit in the middle of that argument. trialforum
  • What it is: Synthetic small-molecule pan-agonist of estrogen-related receptors ERRα, ERRβ, and ERRγ (acyl-hydrazide; CAS 303760-60-3; MW ~290.3). Research tool compound from the Burris lab / Saint Louis University line — not an approved drug, not a peptide. trial
  • Mechanism (plain): ERR activation (especially ERRα-leaning potency) turns up aerobic / fat-oxidation / mitochondrial gene programs (PGC-1α axis adjacency), not classic stimulant or appetite-suppression pathways. trial
  • Evidence level: Strong preclinical mouse metabolic and endurance data; Xu et al. Circulation heart-failure model also positive preclinically. No robust human RCTs or Phase 1 PK for gray-market claims. trial

Stacks 10

  • Top dual stack: SLU-PP-332 + 5-Amino-1MQ — most-named biohacker pairing (ERR oxidative program + NNMT / NAD-adjacent metabolic talk). forum
  • Triple metabolic: SLU + 5-Amino-1MQ + MOTS-c appears in synergy write-ups (mitochondrial / AMPK adjacency); attribution gets muddy fast. forum
  • Endurance adjacency: Cardarine (GW501516) / other “exercise mimetic” PPARδ talk — dual nuclear-receptor cut/cardio stacks; cardarine carries its own rodent carcinogenicity flag. forum
  • GLP-1 era stacks: Retatrutide or other incretins for appetite deficit + SLU for “oxidative tone / muscle fuel” theory — no published combo data. forum
  • NAD support: NMN, NR, or NAD+ injectables listed alongside for mitochondrial narrative synergy. forum
  • Cut stacks: Sometimes under SARMs, yohimbine/stim fat-burners, or AOD-9604 — multi-agent confounds. forum
  • BAM15 / uncoupler talk: Occasional pairing with mitochondrial uncouplers in advanced threads — risk stacking, not mainstream. forum
  • vs 915 swap: Some users plan “inject 332 or oral 915” rather than stacking both. forum
  • Don’t dual-ERR by default: 2026 advice is usually 332 inject *or* 915 oral, not both pan-agonists stacked. forum
  • Real stack: Progressive cardio + calorie control still credited whenever outcomes look good. forum

Access talk 1

  • [object Object]

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 17

  • Energy crash / biphasic feel: Wired or warm window then fatigue, especially when experimental dose is high. forum
  • Sweating / heat / hot flashes: Excess sweat or “over-spun” thermogenic feel is among the most common self-reports when something is felt. forumanecdote
  • Heart rate: Elevated resting or training HR reported in some human logs; mouse telemetry / observational HR increases also discussed in secondary safety write-ups — monitor context, not proven safe. animalforum
  • Sleep: Late dosing linked to worse sleep in some anecdotes; many keep dosing morning-only. anecdote
  • GI: High oral mg and some capsule runs → stomach discomfort, nausea. forum
  • Hunger paradox: Occasional logs of increased hunger at higher oral experiments — opposite of “effortless cut” marketing. anecdote
  • Source / purity risk: Underdose, mislabel, wrong molecule, or non-dissolving powder → false negatives or false confidence. forum
  • Oral-F false negative: Interpreting “capsules failed” as “ERR agonism does nothing” confuses absorption with mechanism. forumtrial
  • Fake-45% / vendor oral-F claims: Marketing “high oral bioavailability” for parent 332 is the red flag 2026 threads check against the 915 paper. forumtrial
  • Identity mix-up: 332 and 915 are different scaffolds; COA/name swaps are part of the access risk. forum
  • Access / RUO: Gray-market research chemical. Not a compounded pharmacy ERR pill in standard talk. forum
  • Unknown human safety: No large human safety database; long-term cardiac, hepatic, endocrine, and oncologic risk of chronic pan-ERR agonism is open. trial
  • Cardiac nuance: Preclinical HF model was protective, not a human cardiac green light; ERR biology in heart is real and double-edged without clinical data. animaltrial
  • Not exercise replacement: Preclinical only; sedentary “pill replaces gym” framing is marketing, not established human outcome data. forum
  • Anti-doping / sport: ERR agonists are on researchers’ and clean-sport radar as potential performance agents; metabolite characterization already published. trial
  • Conflict-of-interest honesty: Much primary efficacy work is single-lineage (Burris lab) with disclosed commercial interest in ERR agonists — independent replication of efficacy endpoints is limited. trial
  • Legal / RUO status: Research chemical / not FDA-approved for human use; jurisdiction and possession rules vary. trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →